NCT00901199View on ClinicalTrials.gov

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
ThalassemiaIron Overload
Interventions
DRUG

Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)

All subjects will be given Deferasirox 20-30 mg/kg for 7 days per week. All subject will be given Deferoxamine 50 mg/kg for 3-7 days per week. The number of days for Deferoxamine will be determined by liver iron concentration at baseline.

Trial Locations (1)

94609

CHRCO, Oakland

All Listed Sponsors
lead

Elliott Vichinsky

OTHER

NCT00901199 - Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload | Biotech Hunter | Biotech Hunter